Observational studyPancreas2026

Nimotuzumab Plus Gemcitabine-based Adjuvant Chemotherapy for Resectable Pancreatic Cancer: A Retrospective Observational Study.

Siyi Zou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.